Overview
Portfolio
More
Mckennymcfarlane Capital
London, United Kingdom
Invests in early and growth-stage companies across finance, healthcare, food & beverage, agriculture, sustainability, and technology, focusing on profitable innovation with positive environmental, social, or technolo...
Portfolio
11+
Employees
5+
Founded
2019
AUM
N/A
Investment focus
Stages
No stages listed
Industries
No industries listedGeographic scope
United KingdomNetherlandsUnited States
Sources
Mckennymcfarlane Capital
Invests in early and growth-stage companies across finance, healthcare, food & beverage, agriculture, sustainability, and technology, focusing on profitable innovation with positive environmental, social, or technological impact.
Portfolio
11+
Employees
5+
Founded
2019
AUM
N/A
Stages
No stages listed
Industries
No industries listedGeographic scope
United KingdomNetherlandsUnited States
Sources
Showing 7 of 7 matched portfolio companies
The startup has developed a non-invasive blood glucose monitoring device that transforms any smartwatch into a glucose tracking tool, providing real-time alerts for high and low glucose levels. This technology enables diabetes patients to achieve accurate measurements and track health trends, thereby improving daily management and reducing the risk of complications.
15+
1K+Approximate amount of employees
Funding: $17.4M
Rough estimate of the amount of funding raised
Funding: $17.4M
Rough estimate of the amount of funding raised
Brightseed utilizes its Forager® AI platform to identify and map bioactive compounds in plants, revealing their specific health benefits and connections to human biology. The company addresses the challenge of underutilized plant compounds by providing science-backed natural health solutions, such as its Bio Gut Fiber, which supports gut health through pre-clinical bioactive insights.
Funding: $111.9M
Rough estimate of the amount of funding raised
Funding: $111.9M
Rough estimate of the amount of funding raised
Klotho Therapeutics is developing recombinant human Klotho proteins to enhance kidney function and mitigate age-related diseases, including cognitive decline and cancer. By targeting the biological mechanisms of aging, their therapy aims to improve healthspan and reduce the incidence of chronic conditions associated with low Klotho levels.
Funding: $10.0M
Rough estimate of the amount of funding raised
Funding: $10.0M
Rough estimate of the amount of funding raised
Life Biosciences is developing cellular rejuvenation therapies that target specific biological mechanisms of aging to reverse and prevent age-related diseases. Their approach aims to provide therapeutic options for chronic conditions that currently lack effective treatments.
Funding: $175.2M
Rough estimate of the amount of funding raised
Funding: $175.2M
Rough estimate of the amount of funding raised
NeedleSmart digitizes vaccination administration by capturing structured data at the point of care and syncing it directly with major EHR systems, eliminating manual charting. Real‑time dashboards provide safety monitoring, inventory tracking, and automated compliance reporting for hospitals, clinics, and public health agencies.
RightIndem offers a white-label digital claims platform that enables insurers to automate the claims process through user-friendly interfaces and API integrations, allowing claimants to submit claims anytime, anywhere. This technology reduces the average claims lifecycle by four days and increases user satisfaction, with 86% of customers finding the platform easy to use.
Funding: $1.0M
Rough estimate of the amount of funding raised
Funding: $1.0M
Rough estimate of the amount of funding raised
This startup manufactures biodegradable packaging products using bio-resin and coated paper as sustainable alternatives to single-use plastics. Their solutions aim to significantly reduce plastic pollution by providing commercial clients with effective substitutes for millions of plastic straws.
Funding: $77.1M
Rough estimate of the amount of funding raised
Funding: $77.1M
Rough estimate of the amount of funding raised
Showing 4 of 4 unmatched portfolio companies